WallStSmart
FEMY

Femasys Inc

NASDAQ: FEMY · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$0.38
-1.75% today

Updated 2026-06-02

Market cap
$925180.00
P/E ratio
P/S ratio
0.40x
EPS (TTM)
$-4.80
Dividend yield
52W range
$0 – $1
Volume
1.1M

Femasys Inc (FEMY) Financial statements

SEC filings — annual and quarterly data.

Cash flow — annual

Item2019202020212022202320242025
Operating cash flow$-11.01M$-4.93M$-7.93M$-10.73M$-11.28M$-19.44M$-18.69M
Capital expenditures$696499.00$31681.00$306868.00$407475.00$143917.00$761706.00$525007.00
Depreciation
Stock-based comp$358841.00$318640.00$193366.00$224939.00$675700.00$444147.00$790145.00
Free cash flow$-11.70M$-4.96M$-8.24M$-11.14M$-11.42M$-20.21M$-19.22M
Investing cash flow
Financing cash flow
Dividends paid
Share repurchases
Debt repayment
Net change in cash

Frequently asked questions

What is Femasys Inc's revenue?

Femasys Inc's trailing twelve-month revenue is $2.29M. Revenue is the top line the whole model builds on, and at this scale the question shifts from how fast it grows to whether margins hold as it compounds.

How profitable is FEMY?

In its most recent fiscal year, FEMY ran a gross margin of 61.96%, an operating margin of -766.95%, and a net margin of -812.27%. Margins this high mean most of each extra dollar of revenue drops through to profit, which is the signature of real pricing power.

How much free cash flow does FEMY generate?

FEMY produced $-19.22M in free cash flow in its most recent fiscal year. Free cash flow is what is left after running and reinvesting in the business, and it is the cash that actually funds buybacks, dividends, and a stronger balance sheet.

Is FEMY's balance sheet healthy?

FEMY holds $9.27M in cash and equivalents against $3.18M in long-term debt, on $5.87M of shareholder equity. Cash on hand exceeds long-term debt, so the balance sheet adds little financial risk to the thesis.